Currently submitted to: Journal of Medical Internet Research
Date Submitted: Jul 23, 2020
Open Peer Review Period: Jul 23, 2020 - Aug 2, 2020
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer-Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
How Can We Optimize the Readability and Format of Plain Language Summaries for Medical Journal Articles? A Cross-sectional Survey Study
Plain language summaries (PLS) are intended to provide readers with a clear, non-technical, and easily understandable overview of medical and scientific literature; however, audience preferences for specific PLS format have yet to be fully explored.
To evaluate the preferred readability level and format for PLS of medical journal articles across different disease states, with online audiences from various age groups.
Articles describing phase III clinical trials from top-level, peer-reviewed journals published between May 2016–May 2018 were identified for three disease states representing a range of patient age groups (psoriasis, a skin disease [younger patients]; multiple sclerosis [MS], a nerve-based disease [middle-aged patients]; and rheumatoid arthritis [RA], a painful joint disease [older patients]). Four PLS were developed for each article: three as text only (written with high-, medium-, and low-complexity) and one as an infographic. To evaluate each of the four PLS formats, a 20-question survey (specific to one of the three diseases) was sent to a representative sample, via UK-based patient association websites, Twitter, and Facebook patient groups. A weighted-average calculation was applied to responders’ ranked preferences for each PLS format.
Across all three diseases, the weighted-average preference scores showed that infographics (psoriasis=2.91; MS=2.71; RA=2.78) and medium-complexity text PLS (reading age: 14–17 years, US Grade 9–11; psoriasis=2.90; MS=2.47; RA=2.77) were the two most-preferred PLS formats in each case.
Audience preferences should be accounted for when preparing PLS to accompany original peer-reviewed research articles. Oversimplified text can be viewed negatively, and infographic versions or medium-complexity text appear to be the most popular.
Request queued. Please wait while the file is being generated. It may take some time.
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.